Fenebrutinib：Fenebrutinib in H1 antihistamine
Fenebrutinib in H1 antihistamine
由MMetz著作·2021·被引用52次—Fenebrutinibdiminisheddiseaseactivityinpatientswithantihistamine-refractoryCSU,includingmorepatientswithrefractorytypeIIb ...。其他文章還包含有：「Genentech:PressReleases|Tuesday」、「Fenebrutinib」、「Fenebrutinib」、「Fenebrutinib(GDC-0853)」、「InvestigationofFenebrutinibMetabolismandBioactivation...」、「臨床試驗結果摘要」、「ResultsofaPhaseII,Randomized,Double」
查看更多 離開網站
Genentech: Press Releases | Tuesday
https://www.gene.com
Fenebrutinib is an investigational oral, reversible and non-covalent BTK inhibitor that blocks the function of BTK. BTK, also known as tyrosine- ...
Fenebrutinib
https://pubchem.ncbi.nlm.nih.g
Fenebrutinib is an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, fenebrutinib ...
Fenebrutinib
https://www.mssociety.org.uk
Fenebrutinib is a new drug being investigated for the treatment of relapsing and primary progressive MS. Phase 2 and 3 trials are currently recruiting ...
Fenebrutinib (GDC-0853)
https://www.medchemexpress.com
Fenebrutinib (GDC-0853) is a potent, selective, orally available, and noncovalent bruton's tyrosine kinase (Btk) inhibitor with Kis of 0.91 nM, 1.6, 1.3, 12.6, ...
Investigation of Fenebrutinib Metabolism and Bioactivation ...
https://pubmed.ncbi.nlm.nih.go
Fenebrutinib is an orally available Bruton tyrosine kinase inhibitor. It is currently in multiple phase III clinical trials for the ...
臨床試驗結果摘要
https://forpatients.roche.com
fenebrutinib 或安慰劑（一種看起來像fenebrutinib 但不含藥物的藥丸）。 • 本試驗在11 國納入160 位患者。 • 主要的發現，是fenebrutinib 的安全性足以由本試驗的患者耐受 ...
Results of a Phase II, Randomized, Double
https://pubmed.ncbi.nlm.nih.go
Objective: Fenebrutinib (GDC-0853) is a noncovalent, oral, and highly selective inhibitor of Bruton's tyrosine kinase (BTK). The efficacy, safety, and ...